source
- GLP-1 drugs shift from obesity treatment to lifestyle products, prompting setbacks for Merck and DaiichiThe column notes that GLP-1 medicines, originally marketed to treat obesity as a medical condition, are now being promoted more as general lifestyle enhancers for appearance and wellbeing. Novo No…
- Roche halts obesity antibody emugrobart after negative phase 2 interim readoutRoche has stopped development of its obesity antibody emugrobart after an interim analysis of a phase 2 trial indicated a low chance of meeting the study endpoints. The antibody, designed to block…